Essential Reads:Â Clinical Challenges in the Treatment of Perimenopausal Women with Schizophrenia
Women with schizophrenia may experience worsening of their symptoms as they transition into the menopause.Â
Women with schizophrenia may experience worsening of their symptoms as they transition into the menopause.Â
Around 10 years ago, there was a series of publications suggesting a link between the use of serotonin reuptake inhibitor antidepressants and bone loss in older women. Â One of the things that made it difficult [...]
Many women report cognitive difficulties — forgetfulness, distractibility, feeling foggy —during the transition to menopause. While much attention has been devoted to the treatment of vasomotor symptoms, such as hot flashes or night sweats, less [...]
Aromatase inhibitors (AIs) are the preferred hormonal therapy for postmenopausal women with estrogen sensitive breast cancer. While the selective estrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, are used in premenopausal women with estrogen sensitive breast cancer, the aromatase inhibitors (e.g., anastrozole, letrozole, and exemestane) have been shown to be more effective and safer than the SERMs in postmenopausal women.Â